<div id="readability-page-1">HUTCHMED (China) ( (HK:0013) ) has shared an update.HUTCHMED reported pivotal Phase II data for its FGFR1/2/3 inhibitor fanregratinib in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, showing an independent review objective response rate of 42.5% and a disease control rate of 83.9%. The single-arm China-based trial also delivered a median duration of response of 6.9 months, progression-free survival of 6.9 months and overall survival of 16.6 months, with rapid onset of action and a manageable safety profile marked mainly by elevated liver enzymes and palmar-plantar erythrodysesthesia.Supported by these data, China’s National Medical Products Administration has accepted and granted priority review to a New Drug Application for fanregratinib in previously treated advanced, metastatic or unresectable intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements. If approved, fanregratinib could become an important targeted option for a hard-to-treat biliary tract cancer segment, strengthening HUTCHMED’s oncology portfolio and reinforcing its position in the fast-growing market for precision cancer therapies in China. The most recent analyst rating on (HK:0013) stock is a Hold with a HK$21.30 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page. <div> More about HUTCHMED (China) HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. It develops drug candidates in-house and has three medicines marketed in China, with its first product also approved in major global markets including the US, Europe and Japan. Average Trading Volume: 4,605,110 Technical Sentiment Signal: Sell Current Market Cap: HK$13.83B </div><div> Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page. </div></div>

00013

HUTCHMED reported strong Phase II data for fanregratinib in FGFR2-positive cholangiocarcinoma, showing a 42.5% response rate. China's NMPA granted priority review to its New Drug Application. Approval could strengthen HUTCHMED's oncology portfolio. The stock currently holds a 'Hold' rating with a HK$21.30 target.

HUTCHMED’s Fanregratinib Delivers Strong Phase II Data in FGFR2-Positive Cholangiocarcinoma